logo
Father made OBE for defibrillator campaign after 12-year-old son's death

Father made OBE for defibrillator campaign after 12-year-old son's death

The Oliver King Foundation has since given out 7,000 defibrillators, and Mr King's campaigning led to the Government ensuring every state school in England has access to one of the life-saving machines.
He said: 'Our Ollie was only with us for 12 years but he never let us down once and this is us not letting his name down.'
Mr King, 63, said when he first found out he was to be included in the King's Birthday Honours he thought the letter had gone to the wrong address.
He said: 'I'm not one for awards, I just want to march on. I'm just a dad, that's it, I'm a dad.
'But, for an OBE to come through – I was cartwheeling in the garden!'
He said Oliver was 'very sporty', 'always had a football under his arm' and was about to sign for Everton, but unknown to the family he had a genetic condition passed down from his father which led to his cardiac arrest.
Mr King is working to set up a centre to provide testing for all children to see if they have the gene.
He said: 'The morning that he had his cardiac arrest he was swimming.
'If you have this genetic condition that's the worst thing you can do… because when you go in the water, you know that little shock, it's an adrenalin rush, and that can send you into cardiac arrest.
'Unfortunately for us, that happened to our Ol.'
The foundation has been supported by figures including former Liverpool footballer Jamie Carragher (Mike Egerton/PA)
Since the foundation was set up in 2012, Mr King has personally delivered all the defibrillators to schools, businesses and sporting venues as far north as Stornoway and as far south as Portsmouth.
Mr King said 84 lives had been saved with the defibrillators, including a child as young as four.
He said: 'When you get the emails through off the parents, I still get the same feeling as though it's the first one. I know it's not a tally but a life has been saved – maybe our Oliver's life would have been saved if someone would have done what we're doing now.'
He said the lives had been saved in Oliver's name, adding: 'Not mine, I'm only carrying his torch.'
The foundation, which also provides training to use the machines, has received support from former Liverpool footballer Jamie Carragher, as well as politicians including Liverpool Garston MP Maria Eagle, Lord Mike Storey and Lord Stuart Polak.
Mr King, of Childwall, Liverpool, said he had dealt with six prime ministers during his time as a campaigner.
He said: 'It's like setting a business up – you could fail or you could march on. In this particular case we marched on and got stronger and stronger and stronger. I don't have a reverse gear.'
He said he plans to continue his campaign and is calling for a change in the law which would see defibrillators required in all public buildings, in the same way as fire extinguishers.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Government partners with Mounjaro maker to tackle obesity
Government partners with Mounjaro maker to tackle obesity

Powys County Times

time26 minutes ago

  • Powys County Times

Government partners with Mounjaro maker to tackle obesity

The Government has joined forces with the pharmaceutical giant that makes weight loss jab Mounjaro in a bid to tackle obesity. The move could see patients accessing care at pharmacies or by using online platforms. The £85 million programme from Eli Lilly and the Department for Science, Innovation and Technology (DSIT) has been designed to look at how obese patients can access weight management care more easily. This includes through community services, in pharmacies and online. Using these tools, eligible patients could be treated 'in a matter of months', according to Health Secretary Wes Streeting. Under the agreement, the Government will contribute up to £50 million in UK-wide investment. Meanwhile, Eli Lilly will back the programme with £35 million, and NHS organisations will be able to apply for a share of the funding. Successful applicants can then use the cash to run and assess a pilot to build evidence for efficient obesity care in the UK. Eligible patients could be able to access these innovative services by summer 2026, the Government said. Mr Streeting warned that obesity is one of the leading causes of ill health and costs the health service billions. 'Yet, we now have the science, technology and knowledge to help tackle the obesity epidemic, if we seize this opportunity,' he added. 'This collaboration will help patients living with obesity in a matter of months – through testing better access to weight loss services and treatments. 'In the long-term it will inform how we can better tackle one of the biggest modern day health challenges and, through our Plan for Change, create an NHS that is fit for the future.' Science and Technology Secretary Peter Kyle said new ways of accessing support 'could be transformational for people's quality of life, and for society'. They could free obese people from 'ill-health that holds them back in daily life – while reducing the strain on our NHS', he added. NHS England national medical director Dr Claire Fuller said: 'Obesity is one of the biggest public health challenges we face and costs the NHS billions of pounds every year, so this collaboration between government and industry to drive new ways of supporting people with obesity could make a huge difference. 'The NHS is already developing and rolling out a range of ways to help people to manage their weight and live healthier lives, with patients benefiting from wraparound care from local weight management teams and via online support services, but we are excited by the potential of this collaboration to accelerate efforts to tackle obesity as the NHS moves from treatment to prevention as part of the 10-Year Health Plan.' Professor Rachel Batterham, senior vice president for international medical affairs at Lilly said: 'The launch of this programme marks an important milestone in advancing new models of care for obesity.' Henry Gregg, chief executive of the National Pharmacy Association, welcomed the announcement but warned that funding should cover costs for pharmacies. 'This is a vital step forward in addressing one of the most pressing health challenges facing our country,' he said. 'It's important that any funding made available is sufficient to cover the costs involved for pharmacies to provide wraparound care and support. 'Community pharmacies already support over 1.4 million people every month with weight management services delivered by pharmacists who are highly trained professionals providing expert, accessible care. 'Despite this, the current NHS rollout remains extremely limited, with only a small number of eligible patients receiving support for obesity with weight loss treatments, and it is vital that this changes. 'With the right funding, pharmacies can scale up delivery quickly – ensuring more people get the help they need, when and where they need it.' News of the programme comes after Lilly published the results of a trial assessing a new daily pill for weight loss, which could offer a new and convenient alternative to jabs. People taking orforglipron lost an average of 12.3 kilograms in 72 weeks compared with those not taking the drug. The phased NHS roll-out of Lilly's weight loss jab Mounjaro to patients in England started in June for patients with a body mass index (BMI) over 40 and at least four co-morbidities.

Government partners with Mounjaro maker to tackle obesity
Government partners with Mounjaro maker to tackle obesity

South Wales Argus

timean hour ago

  • South Wales Argus

Government partners with Mounjaro maker to tackle obesity

The move could see patients accessing care at pharmacies or by using online platforms. The £85 million programme from Eli Lilly and the Department for Science, Innovation and Technology (DSIT) has been designed to look at how obese patients can access weight management care more easily. This includes through community services, in pharmacies and online. Using these tools, eligible patients could be treated 'in a matter of months', according to Health Secretary Wes Streeting. Under the agreement, the Government will contribute up to £50 million in UK-wide investment. Meanwhile, Eli Lilly will back the programme with £35 million, and NHS organisations will be able to apply for a share of the funding. Successful applicants can then use the cash to run and assess a pilot to build evidence for efficient obesity care in the UK. Eligible patients could be able to access these innovative services by summer 2026, the Government said. Mr Streeting warned that obesity is one of the leading causes of ill health and costs the health service billions. 'Yet, we now have the science, technology and knowledge to help tackle the obesity epidemic, if we seize this opportunity,' he added. Mounjaro, which is made by Eli Lilly, has been dubbed the 'King Kong' of weight loss drugs (Alamy/PA) 'This collaboration will help patients living with obesity in a matter of months – through testing better access to weight loss services and treatments. 'In the long-term it will inform how we can better tackle one of the biggest modern day health challenges and, through our Plan for Change, create an NHS that is fit for the future.' Science and Technology Secretary Peter Kyle said new ways of accessing support 'could be transformational for people's quality of life, and for society'. They could free obese people from 'ill-health that holds them back in daily life – while reducing the strain on our NHS', he added. NHS England national medical director Dr Claire Fuller said: 'Obesity is one of the biggest public health challenges we face and costs the NHS billions of pounds every year, so this collaboration between government and industry to drive new ways of supporting people with obesity could make a huge difference. 'The NHS is already developing and rolling out a range of ways to help people to manage their weight and live healthier lives, with patients benefiting from wraparound care from local weight management teams and via online support services, but we are excited by the potential of this collaboration to accelerate efforts to tackle obesity as the NHS moves from treatment to prevention as part of the 10-Year Health Plan.' Professor Rachel Batterham, senior vice president for international medical affairs at Lilly said: 'The launch of this programme marks an important milestone in advancing new models of care for obesity.' Henry Gregg, chief executive of the National Pharmacy Association, welcomed the announcement but warned that funding should cover costs for pharmacies. 'This is a vital step forward in addressing one of the most pressing health challenges facing our country,' he said. 'It's important that any funding made available is sufficient to cover the costs involved for pharmacies to provide wraparound care and support. 'Community pharmacies already support over 1.4 million people every month with weight management services delivered by pharmacists who are highly trained professionals providing expert, accessible care. 'Despite this, the current NHS rollout remains extremely limited, with only a small number of eligible patients receiving support for obesity with weight loss treatments, and it is vital that this changes. 'With the right funding, pharmacies can scale up delivery quickly – ensuring more people get the help they need, when and where they need it.' News of the programme comes after Lilly published the results of a trial assessing a new daily pill for weight loss, which could offer a new and convenient alternative to jabs. People taking orforglipron lost an average of 12.3 kilograms in 72 weeks compared with those not taking the drug. The phased NHS roll-out of Lilly's weight loss jab Mounjaro to patients in England started in June for patients with a body mass index (BMI) over 40 and at least four co-morbidities. Over the next three years, about 240,000 patients are expected to be eligible for the treatment.

Government partners with Mounjaro maker to tackle obesity
Government partners with Mounjaro maker to tackle obesity

Rhyl Journal

time2 hours ago

  • Rhyl Journal

Government partners with Mounjaro maker to tackle obesity

The move could see patients accessing care at pharmacies or by using online platforms. The £85 million programme from Eli Lilly and the Department for Science, Innovation and Technology (DSIT) has been designed to look at how obese patients can access weight management care more easily. This includes through community services, in pharmacies and online. Using these tools, eligible patients could be treated 'in a matter of months', according to Health Secretary Wes Streeting. Under the agreement, the Government will contribute up to £50 million in UK-wide investment. Meanwhile, Eli Lilly will back the programme with £35 million, and NHS organisations will be able to apply for a share of the funding. Successful applicants can then use the cash to run and assess a pilot to build evidence for efficient obesity care in the UK. Eligible patients could be able to access these innovative services by summer 2026, the Government said. Mr Streeting warned that obesity is one of the leading causes of ill health and costs the health service billions. 'Yet, we now have the science, technology and knowledge to help tackle the obesity epidemic, if we seize this opportunity,' he added. 'This collaboration will help patients living with obesity in a matter of months – through testing better access to weight loss services and treatments. 'In the long-term it will inform how we can better tackle one of the biggest modern day health challenges and, through our Plan for Change, create an NHS that is fit for the future.' Science and Technology Secretary Peter Kyle said new ways of accessing support 'could be transformational for people's quality of life, and for society'. They could free obese people from 'ill-health that holds them back in daily life – while reducing the strain on our NHS', he added. NHS England national medical director Dr Claire Fuller said: 'Obesity is one of the biggest public health challenges we face and costs the NHS billions of pounds every year, so this collaboration between government and industry to drive new ways of supporting people with obesity could make a huge difference. 'The NHS is already developing and rolling out a range of ways to help people to manage their weight and live healthier lives, with patients benefiting from wraparound care from local weight management teams and via online support services, but we are excited by the potential of this collaboration to accelerate efforts to tackle obesity as the NHS moves from treatment to prevention as part of the 10-Year Health Plan.' Professor Rachel Batterham, senior vice president for international medical affairs at Lilly said: 'The launch of this programme marks an important milestone in advancing new models of care for obesity.' Henry Gregg, chief executive of the National Pharmacy Association, welcomed the announcement but warned that funding should cover costs for pharmacies. 'This is a vital step forward in addressing one of the most pressing health challenges facing our country,' he said. 'It's important that any funding made available is sufficient to cover the costs involved for pharmacies to provide wraparound care and support. 'Community pharmacies already support over 1.4 million people every month with weight management services delivered by pharmacists who are highly trained professionals providing expert, accessible care. 'Despite this, the current NHS rollout remains extremely limited, with only a small number of eligible patients receiving support for obesity with weight loss treatments, and it is vital that this changes. 'With the right funding, pharmacies can scale up delivery quickly – ensuring more people get the help they need, when and where they need it.' News of the programme comes after Lilly published the results of a trial assessing a new daily pill for weight loss, which could offer a new and convenient alternative to jabs. People taking orforglipron lost an average of 12.3 kilograms in 72 weeks compared with those not taking the drug. The phased NHS roll-out of Lilly's weight loss jab Mounjaro to patients in England started in June for patients with a body mass index (BMI) over 40 and at least four co-morbidities. Over the next three years, about 240,000 patients are expected to be eligible for the treatment.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store